Robert Lowsky

Clinical Focus

• Cancer > Bone Marrow Transplant
• Cancer > Hematology
• Blood and Marrow Transplantation
• Hematology

Professional Education

• Toronto General Hospital (1993) Canada
• Board Certification: Internal Medicine, Royal College of Physicians and Surgeons (1992)
• Toronto General Hospital (1991) Canada
• Toronto General Hospital (1989) Canada
• McGill University (1988) Canada
• FRCP, Coll of Physicians/Surgs Canada Hematology (1993)
• FRCP, Coll of Physicians/Surgs Canada Internal Medicine (1991)
• MD, McGill University Medicine (1988)

Research Interests

Dr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.

Clinical Trials

• Allogeneic HCT using Nonmyeloablative Host Conditioning with TLI & ATG vs SOC in AML Recruiting
• Allogeneic Hematopoietic Cell Transplantation Using TLI/ATG for Older Patients with Hematologic Malignancies Recruiting
• Allogeneic Transplantation From Related Haploidentical Donors in Older Patients with Indolent Hematologic Malignancies Recruiting
• TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD Recruiting
• A Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft versus Host Disease Recruiting
• Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Recruiting
• Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Recruiting
• Defibrotide for Hematopoietic SCT Patients With Severe Hepatic VOD: a Treatment IND Study Recruiting
• Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease Recruiting
• Imatinib Mesylate and Nilotinib After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Recruiting
• NMDP Research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation Recruiting
• Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG Recruiting
• Ph II of Non-myeloablative Allgnc Trnsplnt Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Recruiting
• Phase II Poor Risk Diffuse Large B-cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT) Recruiting
• Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation Recruiting
• Sirolimus & Mycophenolate Mofetil as GVHD prophylaxis in Myeloablative, Matched Related Donor HCT Recruiting
• Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease Recruiting
• Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) Recruiting
• Allo BMT in Advanced Leukemia or High Grade Lymphoma No longer recruiting
• Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma Completed
• A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation Completed
• Allogeneic Transplantation for Patients with Acute Leukemia or CML No longer recruiting
• Autologous Stem Cell Rescue for Primary Amyloidosis No longer recruiting
• Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients No longer recruiting
• High -Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma No longer recruiting
• High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma No longer recruiting
• Mixed Chimera Allo Transplantation in Multiple Myeloma No longer recruiting
• Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies No longer recruiting
• Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients No longer recruiting
• Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells Completed

Publications

• Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update. Kohrt H,  Lowsky R.  Curr Opin Hematol.  2009; 16 (6): 460-5
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Kohrt HE,  Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R.  Blood.  2009; 114 (5): 1099-109
• Total lymphoid irradiation for graft-versus-host disease protection. Kohrt H,  Lowsky R.  Curr Opin Oncol.  2009; 21 Suppl 1 S23-6
• Tolerance and chimerism after renal and hematopoietic-cell transplantation. Scandling JD,  Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S.  N Engl J Med.  2008; 358 (4): 362-8
• High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Law LY,  Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.  Biol Blood Marrow Transplant.  2006; 12 (7): 703-11
• Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Cao TM,  Shizuru JA, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Stuart MJ, Grumet FC, Negrin RS, Lowsky R.  Blood.  2005; 105 (6): 2300-6
• CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Cao TM,  Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Negrin RS, Lowsky R.  Exp Hematol.  2005; 33 (3): 279-85
• A technique of bone marrow collection from vertebral bodies of cynomolgus macaques for transplant studies. Flores MG,  Holm B, Larson MJ, Lau MK, Si MS, Lowsky R, Rousvoal G, Grumet FC, Strober S, Hoppe R, Reitz BA, Borie DC.  J Surg Res.  2005; 124 (2): 280-8
• Protective conditioning for acute graft-versus-host disease. Lowsky R,  Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S.  N Engl J Med.  2005; 353 (13): 1321-31
• Short tandem repeat analysis to monitor chimerism in macaca fascicularis. Lau M,  Vayntrub T, Grumet FC, Lowsky R, Strober S, Hoppe R, Larson M, Holm B, Reitz B, Borie D.  Am J Transplant.  2004; 4 (9): 1543-8
• Approaches to transplantation tolerance in humans. Strober S,  Lowsky RJ, Shizuru JA, Scandling JD, Millan MT.  Transplantation.  2004; 77 (6): 932-6